This appraisal was due to start at the end of September. However the company, Vertex Pharmaceuticals, has informed us that it will not be participating in the appraisal. As a consequence, we have now suspended this appraisal.
Please monitor this webpage for further updates.
| Status | Suspended |
| Decision | Selected |
| Process | STA 2018 |
| ID number | 1486 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TACommD@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 October 2019 | Suspended. This appraisal was due to start at the end of September. However the company, Vertex Pharmaceuticals, has informed us that it will not be participating in the appraisal. As a consequence, we have now suspended this appraisal. Please monitor this webpage for further updates. |
| 22 August 2019 | Draft scope documents |
| 25 September 2018 - 23 October 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual